Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity
- 10 November 2009
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 77 (2), 247-254
- https://doi.org/10.1124/mol.109.061788
Abstract
The concept of selective receptor modulators has been established for the nuclear steroid hormone receptors. Such selective modulators have been used therapeutically with great success in the treatment of cancer. However, this concept has not been examined with regard to the aryl hydrocarbon receptor (AHR) because of the latent toxicity commonly associated with AHR activation. AHR-mediated toxicity is primarily derived from AHR binding to its dioxin response element (DRE) and driving expression of CYP1 family members, which have the capacity to metabolize procarcinogens to genotoxic carcinogens. Recent evidence using a non-DRE binding AHR mutant has established the DRE-independent suppression of inflammatory markers by the AHR. We wished to determine whether such DRE-independent repression with wild-type AHR could be dissociated from canonical DRE-dependent transactivation in a ligand-dependent manner and, in doing so, prove the concept of a selective AHR modulator (SAhRM). Here, we identify the selective estrogen receptor (ER) modulator Way-169916 as a dually selective modulator, binding both ER and AHR. Inflammatory gene expression associated with the cytokine-inducible acute-phase response (e.g., SAA1 and CRP) are diminished by Way-169916 in an AHR-dependent manner. Furthermore, activation of AHR by Way-169916 fails to stimulate canonical DRE-driven AHR-mediated CYP1A1 expression, thus eliminating the potential for AHR-mediated genotoxic stress. Such anti-inflammatory activity in the absence of DRE-mediated expression fulfills the major criteria of an SAhRM, which suggests that selective modulation of AHR is possible and renders the AHR a therapeutically viable drug target for the amelioration of inflammatory disease.Keywords
This publication has 31 references indexed in Scilit:
- Simultaneous In Vivo Time Course and Dose Response Evaluation for TCDD-Induced Impairment of the LPS-stimulated Primary IgM ResponseToxicological Sciences, 2009
- The aryl hydrocarbon receptor: a perspective on potential roles in the immune systemImmunology, 2009
- Ah receptor represses acute-phase response gene expression without binding to its cognate response elementLaboratory Investigation, 2009
- Ligand Selectivity and Gene Regulation by the Human Aryl Hydrocarbon Receptor in Transgenic MiceMolecular Pharmacology, 2009
- Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cellsThe Journal of Experimental Medicine, 2008
- Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cellsProceedings of the National Academy of Sciences of the United States of America, 2008
- 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Mediated Impairment of B Cell Differentiation Involves Dysregulation of Paired Box 5 (Pax5) Isoform, Pax5aThe Journal of pharmacology and experimental therapeutics, 2008
- The Aryl Hydrocarbon Receptor Affects Distinct Tissue Compartments during Ontogeny of the Immune SystemToxicological Sciences, 2007
- Estrogen receptor and aryl hydrocarbon receptor signaling pathwaysNuclear Receptor Signaling, 2006
- Ah receptor and NF-κB interactions: mechanisms and physiological implicationsChemico-Biological Interactions, 2002